UK 12:02 Tuesday, 6 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
OptiBiotix Health (OPTI) has announced results for the first half of 2024 including “reported revenues decreased by 21.3% to £276K” but also “significantly increased order book and solid sales performance”, so what’s going on here?
Aquis Regulation has not told Optibiotix (OPTI) how it can be legal for Probiotix (PBX) to issue shares without requisite GM approval. But it seems that like regulators at AIM they are clueless poltroons and so the share issuance has gone ahead anyway. What next? Steve O’Hara, the Optibiotix CEO, tells me:
OptiBiotix Health (OPTI) has issued a “Commercial update” announcement including that at end-July the 2024 calendar year sales orders surpassed its 2023 full-year revenue and, with all of its products targeting growing market trends in lifestyle-related health challenges and large partners longer timescales starting to reach initial orders, it “look to the future with a high degree of confidence”. This was also the tone of a chat we enjoyed with CEO Stephen O’Hara today.
You may well say that this a question I have posed more or less every year for the past half decade. And I have been hopeful only for those hopes to be dashed. Mr. Market feels the same way and that is why shares in Optibiotix (OPTI) are, at, just 24.25p.
As corporate broker to Optibiotix (OPTI) Peterhouse will get a direct steer on what it can or cannot say. Late last week it sent an email to selected clients with no forecasts but an overview which is of note. The underlines towards the end are from me and are why I think that the shares, now 28p, could well treble by Christmas. Peterhouse writes:
Nobody really listens to me on Optibiotix (OPTI) any more but it seems that Midas columnist Jo Hart of the Mail on Sunday has more clout. I shall be seeing Jo tomorrow night as it happens. But if you are wondering why Optibiotix shares are up today, the article below is the reason.
Developer of compounds to prevent and manage disease and promote wellness, OptiBiotix Health (OPTI) has announced results for the 2023 calendar year emphasising increased revenue and that it continues to see sales momentum building in 2024 with its highest ever single order of over £200,000 and sales orders in H1 approaching FY 2023. However, what about the bottom-line performance? And, with the shares currently around 16p, are they a buy, hold or sell?
OptiBiotix Health (OPTI) has issued a “Slimbiome study results”-titled announcement including that latest results from human studies carried out at Roehampton University “continue to prove the efficacy of Slimbiome to reduce hunger and food cravings which changes the amount and type of food people eat leading to sustainable weight management”. Following a chat with OptiBiotix Chief Executive Stephen O’Hara, the following is why such studies are potentially highly significant.
OptiBiotix Health (OPTI) has announced a manufacturing agreement for the supply of its Slimbiome-containing products in India, emphasising a significant opportunity there with a growing middle-class in a population of 1.4 billion people and obesity prevalence at above 40%.
A reader who knows a good bit about retail pipes up on the comments board to warn that none of the three Optibiotix (OPTI) products that Boots is meant to be selling appear to be on the shelves. What follows is an email correspondence between myself and CEO Steve O’Hara.
OptiBiotix Health (OPTI) has announced a £1.35 million placing with CEO Steve O’Hara arguing “given the scale of the opportunities, the board has decided to raise additional capital to capitalise on these growth opportunities and build shareholder value”. It hasn’t got off to a very good start – the news sending the shares more than 11.5% down to 21p. But this is an EIS raise, the last OptiBiotix will be able to do, so suggestions of flipping are just wrong.
